Pharma and RxGen Announce Strategic Alliance
Pharma and RxGen Partner to Deliver Seamless and Superior Drug
& Medical Devices Development Services in Ophthalmology.
France, and Hamden, CT, USA, April 19, 2012 - Iris
Pharma, a leading ophthalmic preclinical and clinical contract research
organization (CRO), and RxGen, a specialty preclinical CRO focused on
the development and application of translational research models, have
established a Strategic Alliance to offer fully integrated
“bench-to-bedside” ophthalmology research services
to the global pharmaceutical and biotechnology industries.
the newly forged transatlantic alliance, Iris Pharma can offer
immediate access to RxGen’s nonhuman primate ophthalmic
research models and related preclinical in vivo services, via a
flexible engagement model, that allows customers to benefit from the
combined preclinical and clinical insight, capabilities, and expertise
that RxGen and Iris Pharma collectively represent.
“Our alliance with
RxGen is an exciting development for both companies. For Iris Pharma,
this relationship allows us to add RxGen’s unique
capabilities and expertise to our existing portfolio of research and
development services, completing the full value-chain required to bring
a drug from bench to bedside," said Pierre-Paul Elena, CEO
of Iris Pharma.
“The ability to offer integrated
packages of services and a comprehensive and seamless program of
preclinical and clinical drug development will improve our competitive
position in the marketplace and generate significant value for our
clients”, said Yann Quentric, Head, Business Development
& Marketing of Iris Pharma.
translating discovery to approved therapeutic demands time and cost
efficient program design and management, capitalizing on the best
available preclinical test systems while maintaining a clear eye on the
clinical pathway”, said Matthew Lawrence, CEO of
look forward to working with Iris Pharma to match capabilities with
needs to provide the lowest risk, highest return translational research
“We are pleased to enter into an
alliance with Iris Pharma, as we share a similar commitment to values
critical to advancing Sponsor programs; scientific integrity,
collaborative engagement and superior service”, said
Christopher Stanley, Chief Business Officer of RxGen. “The
unique combination of RxGen’s in vivo ophthalmic capabilities
in nonhuman primates and Iris Pharma’s world leading position
in ophthalmology uniquely positions us to provide superior innovative
and adaptive services that will speed time to market for our
Pharma is an independent CRO specializing in preclinical and clinical
research services in ophthalmology. Founded in 1989 by Dr Pierre-Paul
Elena, Iris Pharma offers expertise in the development of ophthalmic
drugs and ocular medical devices to the pharmaceutical industry and
biotechnology companies worldwide. Iris Pharma services include proof
of concept and GLP-compliant preclinical studies (safety, tolerance,
pharmacokinetics, efficacy), bioanalysis, preclinical formulation,
clinical trials and consulting services. Iris Pharma’s
research facilities are GLP compliant.
For more information, please visit www.iris-pharma.com.
RxGen, Inc. is
a specialty preclinical CRO, providing innovative in vivo disease
modeling and related preclinical research and development services to
meet translational research needs of the global pharmaceutical and
biotechnology industries. RxGen accelerates therapeutic and medical
technology evaluation by the application of in vivo disease modeling
and pharmacokinetic, pharmacodynamics and safety assessments, with deep
therapeutic domain expertise in ophthalmology, central nervous system,
metabolic and cardiac diseases and disorders.
RxGen’s research facilities are AAALAC accredited and GLP
compliant, supporting a range of services, from proof-of-concept
through IND-enabling / regulatory studies.
For more information, please visit www.rx-gen.com.